Page 220 - 2021_07-Haematologica-web

Letters to the Editor
Contributions: SAS and URP conceived and designed the research; SAS performed statistical analysis; SAS, PD and URP analyzed and interpreted data; SAS and URP wrote the manuscript; and SAS, AO, SOC, PD, QB, BO, PB, RM, KPP, NP, ND, SV, REC and URP critically reviewed and edited the manuscript for important
intellectual content.
References
1. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126-2133.
2. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453- 471.
3. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoi- etic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014;20(1):89-97.
4.Ditschkowski M, Elmaagacli AH, Trenschel R, et al. Dynamic International Prognostic Scoring System scores, pre-transplant thera- py and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012;97(10):1574-1581.
5. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657-2664.
6. Alchalby H, Yunus DR, Zabelina T, et al. Risk models predicting sur- vival after reduced-intensity transplantation for myelofibrosis. Br J Haematol. 2012;157(1):75-85.
7. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010;116(18):3572- 3581.
8. van den Brink MR, Porter DL, Giralt S, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010;16(Suppl 1):S138-145.
9. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-1398.
10. Kroger N, Kvasnicka M, Thiele J. Replacement of hematopoietic sys- tem by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis
Tissue Repair. 2012;5(Suppl 1):S25.
11. Kroger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F
mutation by highly sensitive quantitative real-time PCR after allo- geneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109(3):1316-1321.
12. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation. 2007;83(11):1518-1520.
13. Klyuchnikov E, Holler E, Bornhauser M, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. 2012;159(2):172-181.
14. Bader P, Beck J, Frey A, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant. 1998;21(5):487-495.
15. Thiede C, Bornhauser M, Ehninger G. Strategies and clinical implica- tions of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112(1-2):16-23.
16.Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplanta- tion: separation of graft-versus-leukemia responses from graft-ver- sus-host disease. Blood. 1995;86(4):1261-1268.
17. Thiede C, Lutterbeck K, Oelschlagel U, et al. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. Ann Hematol. 2002;81(Suppl 2):S27-28.
18. Bornhauser M, Oelschlaegel U, Platzbecker U, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009;94(11):1613-1617.
19.Lee HC, Saliba RM, Rondon G, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predic- tive for relapse of acute myeloid leukemia and myelodysplastic syn- dromes. Biol Blood Marrow Transplant. 2015;21(11):1948-1954.
20. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
21. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
1990
haematologica | 2021; 106(7)